title: Development of hyperthyroidism in a patient with idiopathic nephrotic syndrome.
abstract: We present a 13-year-old boy who developed hyperthyroidism during the clinical course of idiopathic nephrotic syndrome treated with glucocorticoid. He had a second relapse of minimal change nephrotic syndrome, and complete remission of nephrotic syndrome was achieved immediately with oral glucocorticoid. However, when the steroid dosage was reduced, signs of hyperthyroidism such as systolic hypertension and tachycardia were observed. Laboratory findings revealed thyroid-stimulating hormone (TSH) below 0.05 microU/ml, free tri-iodothyronine of 16.1 pg/ml, free thyroxine of 5.6 ng/dl, and anti-TSH receptor antibody of 90%. Thus, a diagnosis of hyperthyroidism was made and treatment with thiamazol was started. Massive proteinuria may decrease the activity of hyperthyroidism due to urinary loss of thyroid hormones. A decrease in glucocorticoid dosage may also be involved in the development of hyperthyroidism due to a reduced immunosuppressive effect.
authors.affiliation: Department of Developmental Medicine (Pediatrics), D-5, Osaka University Graduate School of Medicine, Suita City, Osaka 565-0871, Japan.
authors.forename: Takuo
authors.initials: T
authors.lastname: Kubota
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Hirai
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Shimizu
authors.forename: Atsushi
authors.initials: A
authors.lastname: Sawada
authors.forename: Hiroki
authors.initials: H
authors.lastname: Kondou
authors.forename: Shigeo
authors.initials: S
authors.lastname: Nakajima
authors.forename: Tokuzo
authors.initials: T
authors.lastname: Harada
authors.forename: Masaaki
authors.initials: M
authors.lastname: Shima
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006980:Hyperthyroidism / Q000150:complications*; D008297:Male; D009402:Nephrosis, Lipoid / Q000150:complications* / Q000188:drug therapy; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D012008:Recurrence; D012074:Remission Induction
chemical_list: D005938:Glucocorticoids; D011239:Prednisolone